FBXW7-AS1 and Encephalopathy: As efficacy was observed in the acute setting requiring quick-response in 24-hour lethal LPS-encephalopathy rat model, albeit to 50%, data support the potential clinical relevance of DEspR+ subset-specific inhibition.